Mi Sha,Guckian Kevin,Kumaravel Gnanasambandam,Ma Bin,Peng Hairuo,Shao Zhaohui,Sun Lihong,Taveras Arthur,Xin Zhili,Zhang Lei
申请号：
NZ70385113
公开号：
NZ703851A
申请日:
2013.07.26
申请国别(地区):
NZ
年份:
2017
代理人:
摘要：
Sphingosine 1-phosphate (S1P) is a lysophospholipid mediator that evokes a variety of cellular responses including those that result in platelet aggregation, cell proliferation, cell morphology, tumor cell invasion, endothelial cell chemotaxis and angiogenesis. For these reasons, S1P receptors are good targets for therapeutic applications such as autoimmune diseases. S1P receptors make good drug targets because individual receptors are both tissue and response specific. Autotaxin (ATX, ENPP2) is a secreted glycoprotein widely present in biological fluids. Both S1P and ATX are involved in demyelination of the central or peripheral nervous system. The need exists to develop new treatments for patients with demyelination diseases or disorders. The present invention meets this need by providing compounds represented by formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein the compounds are suitable for use in preventing, treating, or reducing symptoms of a condition mediated by S1P activity or autotoaxin (ATX) activity, such as multiple sclerosis, rheumatoid arthritis or chronic pain. Also provided are associated pharmaceutical compositions and methods of use.
